Vir Biotechnology, Inc. — Director's Dealing 2020

Dec 24, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2020-12-22

Reporting Person: Virgin Herbert (EVP, Research & CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-22	Common Stock	M	3805	$1.53	Acquired	27505	Direct
2020-12-22	Common Stock	S	3805	$31.1912	Disposed	23700	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-22	Stock Option (Right to Buy)	$1.53	M	3805	Disposed	2028-01-26	Common Stock (3805)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.1508 to $31.2380 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.